Monoclonal antibodies (monAbs) displaying diverse affinity to native and recombinant mistletoe lectins A-chains (ML I-A, ML II-A, ML III-A and rML-A) have been obtained. In accordance to specificity of monAb they have been classified into three groups: 1. monAb against MLI-A and MLII-A, 2. monAb against MLII-A and MLIII-A, 3. monAb against A-subunits of MLI, MLII and MLIII. The results indicate, that antigen determinants of mistletoe lectins recognized by monAb MNA4, MNA9 and MTC12 do not contain any carbohydrates. Assay of lectins in mistletoe preparations was based on enzyme-linked lectin assay to meet the requirements given in the guidelines for drug tests. In this paper a sandwich ELISA test-system is described which allows to identify each of three ML-toxins. With the detection limits below 3 ng/ml and a linear measuring range of 3-30 ng/ml, dosages of mistletoe lectins in therapeutic range can be assayed. The problems in mistletoe lectins determination, structural differences and nature of heterogeneity of this proteins are discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-0031-1300535 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Promising Role of Plant-Derived Lectins in Oral Cancer Therapeutics: A Systematic Review.
Cureus
December 2024
Department of Oral Pathology, Meenakshi Ammal Dental College, Chennai, IND.
Oral cancer (OC) continues to pose a significant global health challenge, marked by high morbidity and mortality rates despite advances in diagnosis and treatment. Numerous novel potential anticancer drugs have been evaluated, many of which are derived from natural sources, such as microorganisms, plants, and animals. Among these, plant lectins - a distinctive group of proteins and glycoproteins with strong biological activity - have garnered considerable attention over the years.
View Article and Find Full Text PDFSynergistic Effects of Mistletoe Lectin and Cisplatin on Triple-Negative Breast Cancer Cells: Insights from 2D and 3D In Vitro Models.
Int J Mol Sci
January 2025
College of Pharmacy, Sunchon National University, Suncheon 57922, Republic of Korea.
Triple-negative breast cancer (TNBC) remains a challenging subtype due to its aggressive nature and limited treatment options. This study investigated the potential synergistic effects of Korean mistletoe lectin ( L. agglutinin, VCA) and cisplatin on MDA-MB-231 TNBC cells using both 2D and 3D culture models.
View Article and Find Full Text PDFComponent Composition and Features of Biological Activity of Viscum album (Viscaceae).
Dokl Biol Sci
October 2024
Pyatigorsk Medical and Pharmaceutical Institute, Branch of Volgograd State Medical University, Pyatigorsk, Russia.
The review summarizes the data on the chemical composition and some features of biological activity of the European mistletoe Viscum album L. (Viscaceae Batsch). Among secondary metabolites, viscotoxins, lectins, carbohydrates, amino acids, flavonoids, triterpene acids, and nitrogenous compounds predominate in V.
View Article and Find Full Text PDFModulation of Breast Cancer Cell Apoptosis and Macrophage Polarization by Mistletoe Lectin in 2D and 3D Models.
Int J Mol Sci
August 2024
College of Pharmacy, Sunchon National University, Suncheon 57922, Republic of Korea.
Korean mistletoe ( L. var. ) is renowned for its medicinal properties, including anti-cancer and immunoadjuvant effects.
View Article and Find Full Text PDFPharmakokinetics of Mistletoe Lectins after Intravenous Application of a Mistletoe Product in Healthy Subjects.
Pharmaceuticals (Basel)
February 2024
Center for Complementary Medicine, Department of Internal Medicine II, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg im Breisgau, Germany.
Mistletoe lectins (ML) have cytotoxic and immunomodulating properties, and subcutaneously applied mistletoe products (MP) containing ML have approval for supportive cancer treatment. MP are also given off-label intravenously, but data about pharmacokinetics are widely lacking. Therefore, the aim of our phase I trial was to evaluate the pharmacokinetics and safety of intravenously applied natural ML.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!